84-1200-66　Kininogen (KNG) 1ml　K1800-05

特徴

• Human plasma contains at least two distinct forms of kininogen, the carrier molecule of bradykinin, which can be distinguished by their physical, chemical and immunochemical properties.
• They are designated high-molecular-weight kininogen (HMWK) and low-molecular weight kininogen (LMWK).
• HMWK (MW 110000) and LMWK (MW 50000) both liberate bradykinin following the action of kallikrein.
• HMWK circulates as a non-enzymatic factor that is central to contact activation reactions.
• LMWK plays no known role in the activation of coagulation.
• Normal adult plasma levels are 7mg/100ml for HMWK as determined by electroimmunodiffusion and 9mg/100ml based on haemagglutination inhibition assays and RIA.
• Low plasma kininogen levels are seen in newborn and pre-term infants.
• HMWK is absent in congenital kininogen deficiency of the named affected families Fitzgerald and Reid; Williams and Flaujeac lack both HMWK and LMWK.
• The condition is associated with the decreased fibrinolytic activity and kinin formation but is asymptomatic.
• Applications:Suitable for use in ELISA.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:Lyophilized powder may be stored at -20°C.
• Stable for 12 months at -20°C.
• Reconstitute with sterile ddH2O.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• Reconstituted product is stable for 12 months at -20°C.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Further dilutions can be made in assay buffer.